MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$20,499K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities of investments
Accrued liabilities
Stock-based compensation expense
Others
Negative Cash Flow Breakdown
Net loss
Purchases of investments
Net amortization of premiums and...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-32,246
-21,674
-28,273
-40,597
Stock-based compensation expense
4,598
3,454
4,196
1,660
Net amortization of premiums and accretion of discounts on investments
756
792
585
1,184
Depreciation and amortization
552
349
326
1,063
Change in fair value of convertible preferred stock forward
-
-
0
8,928
Prepaid expenses and other assets
-943
85
372
1,998
Accounts payable
983
-3,749
3,851
-4,688
Accrued liabilities
5,954
-4,813
4,297
-1,479
Operating lease liabilities
-344
-193
-139
-591
Deferred revenue
-
-
0
-3,000
Net cash used in operating activities
-20,316
-27,503
-16,699
-59,742
Purchases of short-term investments
-
-
-
38,775
Purchases of investments
17,640
108,776
199,172
-
Maturities of short-term investments
-
-
-
46,500
Maturities of investments
49,117
23,500
84,100
-
Purchase of property and equipment
183
83
104
131
Net cash (used in) provided by investing activities
31,294
-85,359
-122,901
7,594
Proceeds from the sale of common stock in initial public offering, net of offering costs paid
-
-
157,284
-
Proceeds from issuance of convertible preferred stock, net of issuance costs
-
-
0
65,228
Proceeds from private placement financing, net of transaction costs
-58
117,198
-
-
Proceeds from exercise of stock options
732
0
0
6
Payment of deferred offering costs
-
-
-
874
Principal payments of finance lease liability
142
87
86
287
Principal payments of financing obligation
0
0
0
158
Taxes paid related to net share settlement of equity awards
-
-
1,224
-
Net cash provided by (used in) financing activities
532
117,111
156,848
63,915
Net increase (decrease) in cash, cash equivalents and restricted cash
11,510
4,249
17,248
11,767
Cash, cash equivalents and restricted cash - beginning of period
49,727
45,478
28,230
16,463
Cash, cash equivalents and restricted cash - end of period
61,237
-
-
-
Cash and cash equivalents
60,034
-
-
-
Restricted cash
1,203
-
-
-
Total cash, cash equivalents, and restricted cash
61,237
49,727
45,478
28,230
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Maturities of investments
$49,117K
Proceeds from exercise of
stock options
$732K
Net cash (used in)
provided by investing...
$31,294K
Net cash provided by
(used in) financing...
$532K
Canceled cashflow
$17,823K
Canceled cashflow
$200K
Net increase
(decrease) in cash, cash...
$11,510K
Canceled cashflow
$20,316K
Purchases of investments
$17,640K
Purchase of property and
equipment
$183K
Accrued liabilities
$5,954K
Stock-based compensation
expense
$4,598K
Accounts payable
$983K
Prepaid expenses and
other assets
-$943K
Depreciation and
amortization
$552K
Principal payments of
finance lease liability
$142K
Proceeds from private
placement financing, net...
-$58K
Net cash used in
operating activities
-$20,316K
Canceled cashflow
$13,030K
Net loss
-$32,246K
Net amortization of
premiums and accretion of...
$756K
Operating lease
liabilities
-$344K
Buy us a coffee
Evommune, Inc. (EVMN)
Evommune, Inc. (EVMN)